

IN THE CLAIMS:

Please substitute the following amended claim 9 for the original claim having the same number:

34
9. (Amended) A pharmaceutical composition for the treatment of cellular debilitations, derangements and/or dysfunctions and/or other disease states in mammals caused by the development and presence of sporadic basal cell carcinoma, comprising a therapeutically effective amount of inhibitors of the expression and activity of Gli1 and a pharmaceutically acceptable carrier therefor, wherein said inhibitors are selected from the group consisting of small molecule antagonists of Gli1 expression and activity, ligands of Gli1, and agents that exhibit mimicry to Gli1.